TET2-CHIP 변이를 가진 환자에서 콜히친이 관상동맥 죽상경화증 진행에 미치는 영향
TET2-CHIP 변이를 가진 환자에서 콜키신이 관상동맥 죽상경화증 진행에 미치는 영향: 파일럿 임상시험 (COLCHIP-Pilot)
This study aims to investigate whether TET2-associated clonal hematopoiesis of indeterminate potential (TET2-CHIP) can serve as a biomarker to guide precision use of colchicine in a population of clinically stable post-ACS patients receiving standard of care (SoC) therapy. Specifically, we will evaluate whether TET2-CHIP status predicts a differential response to colchicine. As a pilot study, it also aims to provide detailed data supporting design of further trial, such as sample size calculating, endpoint optimizing, etc.
연구 개요
상태
상세 설명
This is a single-center, prospective, randomized, open-label, assessor-blinded pilot trial. A total of 120 patients will be enrolled and stratified by CHIP variant status into a TET2-CHIP group or a non-CHIP group. TET2-CHIP group (N = 60): Participants will be randomized (1:1) to colchicine 0.5 mg once daily plus SoC therapy (n = 30) or SoC therapy alone (control; n = 30). Non-CHIP group (N = 60): Participants will be randomized (1:1) to colchicine 0.5 mg once daily plus SoC therapy (n = 30) or SoC therapy alone (control; n = 30). SoC therapy includes but is not limited to appropriate lipid lowering, anti-platelet therapy, anti-hypertensive and beta blockers as defined by local guidelines. Patients should also be instructed to follow heart healthy (low fat) diet and regular exercise program. The index qualifying ACS must have occurred at least 30 days and no more than 90 days prior to randomization.
Baseline assessment for all participants will include coronary CT angiography (CCTA) using photon-counting detector CT (PCD-CT), inflammatory biomarkers testing and CHIP variant sequencing. After randomization, participants will have visits at Month 0, 1, 3, 6, 9, and 12. Repeat CCTA for the assessment of coronary plaque will occur during the Month 12 visit. The primary endpoint is the percent change in total plaque volume in non-culprit coronary lesion from baseline to Month 12, measured by CCTA. Secondary endpoints include the percent change in other plaques (calcified plaque, noncalcified plaque, low attenuation plaque, and fibrotic plaque) volume of coronary artery plaque from baseline to Month 12; change in levels of inflammatory biomarkers (IL-6, IL-1β, IL-18, hs-CRP, and S100A12); change in the TET2-CHIP variant allele fraction; and major adverse cardiovascular events (MACE), defined as a composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and ischemia-driven revascularization. Participants will be followed for 12 months.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Zaixin Jiang, MD, PhD
- 전화번호: +8618646330195
- 이메일: jzxdr2013@163.com
연구 장소
-
-
Liaoning
-
Shenyang, Liaoning, 중국
- 모병
- General Hospital of Northern Theater Command
-
수석 연구원:
- Yaling Han, MD, PhD
-
연락하다:
- Zaixin Jiang, MD, PhD
- 전화번호: +8618646330195
- 이메일: jzxdr2013@163.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Age 40-85 years;
-
Patients with recent hospitalization for documented ACS (the index event occurring 30-90 days before randomization) and meeting all of the following:
- During the index hospitalization, patients underwent either PCI or diagnostic coronary angiography alone,
- At least one non-culprit coronary lesion with 30%-70% diameter stenosis by visual estimation on coronary angiography,
- Clinically stable throughout the screening period,
- Receiving standard of care therapy for ACS in accordance with national guidelines,
- Peripheral blood DNA available for targeted sequencing, with results demonstrating either TET2-CHIP or no CHIP-associated variants;
-
Written informed consent.
Exclusion Criteria:
- Prior coronary artery bypass grafting (CABG) before documented ACS;
- Other clinically significant cardiovascular diseases, including moderate-to-severe valvular heart disease (moderate or severe), heart failure (NYHA class III-IV), or atrial fibrillation;
- Non-culprit coronary anatomy (e.g., marked tortuosity, bifurcation lesions, or small vessels <1.5 mm in diameter) deemed to preclude plaque assessment by CCTA;
- Planned PCI or CABG;
- Abnormal liver function (ALT >3 times the upper limit of normal range) at randomization;
- Abnormal renal function (serum creatinine >1.5 times the upper limit of normal range or estimated eGFR <45 mL/min/1.73 m²) at randomization;
- Hematologic abnormalities: anemia (hemoglobin <100g/L), thrombocytopenia (platelet count <100×109/L) or leukopenia (white blood cell <3×109/L) at randomization;
- Inflammatory bowel disease (Crohn's or ulcerative colitis) or active diarrhea;
- Symptomatic peripheral neuropathy, pre-existing progressive neuromuscular disease or creatine kinase (CK) level > 3 times the upper limit of normal range as measured within the past 30 days and determined to be non-transient through repeat testing;
- Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception;
- Any contraindication, known allergy or intolerance to colchicine;
- Colchicine use within 30 days prior to randomization, or planned colchicine therapy for other indications;
- Current or planned use of any of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics;
- Existing or planned treatment with other anti-inflammatory or immunosuppressive drugs;
- History of malignancy (hematologic or solid-tumor);
- History of transplantation (hematopoietic stem cell or solid-organ);
- Significant radiation exposure (≥40 mSv) within the past 12 months;
- Known hypersensitivity to iodinated contrast media or uncontrolled active hyperthyroidism;
- Current enrollment in another clinical trial;
- A predicted life expectancy < 1 year;
- Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Colchicine with SoC therapy (TET2-CHIP group)
Participants with TET2-CHIP will receive colchicine 0.5 mg orally once daily plus standard of care (SoC) therapy for 12 months. |
SoC therapy includes but is not limited to appropriate lipid lowering, anti-platelet therapy, anti-hypertensive and beta blockers as defined by local guidelines. SoC therapy |
|
간섭 없음: SoC therapy alone (TET2-CHIP group)
Participants with TET2-CHIP will receive SoC therapy alone (no colchicine) for 12 months. |
|
|
실험적: Colchicine with SoC therapy (non-CHIP group)
Participants without CHIP-associated variants will receive colchicine 0.5 mg orally once daily plus standard of care (SoC) therapy for 12 months. |
SoC therapy includes but is not limited to appropriate lipid lowering, anti-platelet therapy, anti-hypertensive and beta blockers as defined by local guidelines. SoC therapy |
|
간섭 없음: SoC therapy alone (non-CHIP group)
Participants without CHIP-associated variants will receive SoC therapy alone (no colchicine) for 12 months. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent change in total plaque volume of coronary artery plaque
기간: Up to 12 months
|
Percent change in total plaque volume of coronary artery plaque measured by CCTA |
Up to 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent change in other plaques (calcified plaque, noncalcified plaque, low attenuation plaque, and fibrotic plaque) volume of coronary artery plaque
기간: Up to 12 months
|
Percent change in other plaques (calcified plaque, noncalcified plaque, low attenuation plaque, and fibrotic plaque) volume of coronary artery plaque measured by CCTA. |
Up to 12 months
|
|
Change in levels of inflammatory biomarkers
기간: Up to 12 months
|
Change in levels of circulating IL-6, IL-1β, IL-18, hs-CRP, and S100A12. |
Up to 12 months
|
|
Change in TET2-CHIP variant allele fraction at 6 months
기간: Up to 6 months
|
Change in TET2-CHIP variant allele fraction measured by next generation sequencing. |
Up to 6 months
|
|
Change in TET2-CHIP variant allele fraction at 12 months
기간: Up to 12months
|
Change in TET2-CHIP variant allele fraction measured by next generation sequencing. |
Up to 12months
|
|
Major adverse cardiovascular events (MACE)
기간: Up to 12 months
|
A composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and ischemia-driven revascularization. |
Up to 12 months
|
공동 작업자 및 조사자
수사관
- 연구 의자: Yaling Han, MD, PhD, The General Hospital of Northern Theater Command
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- PRECISE
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .